BioCryst Pharma (BCRX) Tops Q2 EPS by 1c; Sees Increase in Net Operating Cash
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.70 +2.35%
Revenue Growth %: +13.7%
Financial Fact:
Product sales: 0
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +13.7%
Financial Fact:
Product sales: 0
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $5.44 million.
Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
- BIG3 Basketball to go public via Graf Global merger at $290 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
